Researchers at the University of Oxford have developed a calculator to assess the risk of serious muscle disorders from statins, finding that over 98% of eligible patients are at low risk.
New Delhi, India Jul 3, 2026 ALN: Researchers at the University of Oxford have developed a new calculator that estimates an individual's risk of developing serious muscle disorders while taking statins. This innovative tool is designed to help both patients and care providers make more informed decisions regarding the use of statins, which are commonly prescribed medications for lowering cholesterol levels and preventing cardiovascular events such as heart attacks and strokes. The calculator's introduction comes at a time when there is significant public concern regarding the side effects associated with statin therapy, particularly muscle-related issues.
The research, published in The Lancet Digital, highlights that over 98% of individuals identified by their general practitioners as eligible for statin therapy were predicted to have a low risk of developing serious muscle disorders in the subsequent decade. These findings indicate that fears surrounding severe muscle-related side effects may be exaggerated for the majority of patients who stand to benefit from statin treatment.
New Tool Aims To Personalize Statin Decisions
In addition to addressing concerns about side effects, the study also identified a significant treatment gap. Over 60% of individuals who were eligible for statin therapy were not utilizing these medications, despite some being at a heightened risk for heart attacks or strokes. The research team believes that the new calculator could foster improved discussions between patients and care providers by offering personalized risk estimates, rather than relying solely on generalized statistics or broad concerns about potential side effects.
The calculator is accessible through the Oxford University Innovation software store and is based on a clinical prediction model that was developed and validated using anonymized records from over 5.6 million individuals registered with general practitioner (GP) practices across England. The model was built using data from more than 1.7 million individuals, and its accuracy was subsequently validated with records from an additional 3.9 million people, ensuring a robust foundation for its predictions.
How the Statin Risk Calculator Works
This model analyzes 22 routinely collected factors to assess the likelihood of developing a serious muscle disorder over one, five, and ten years. These factors encompass a range of demographic and -related variables, including age, sex, ethnicity, body mass index (BMI), smoking status, pre-existing medical conditions, previous muscle problems, vitamin D deficiency, medication use, and whether the individual has been prescribed statins.
Researchers anticipate that the calculator will be utilized alongside existing cardiovascular risk assessment tools, such as QRISK, which evaluates an individual's risk of developing cardiovascular disease. By combining these tools, care professionals can better weigh the benefits of reducing the risk of heart attacks and strokes against the potential risks of serious muscle complications when determining the appropriateness of statin treatment for a given patient.
Putting Statin Side Effects Into Perspective
Statins rank among the most frequently prescribed medications for the prevention of cardiovascular disease. However, concerns regarding muscle-related side effects often deter patients from initiating treatment or lead them to discontinue use, even when the potential benefits of statin therapy are considerable. These concerns can stem from anecdotal reports or misinformation, which can overshadow the clinical evidence supporting the efficacy and safety of statins.
The researchers clarified that their focus is specifically on serious muscle disorders that result in hospital admission or death, rather than the milder muscle aches and pains that some patients report. Previous studies have indicated that many mild muscle symptoms experienced during statin treatment are not directly attributable to the medication and should not serve as a barrier to starting therapy. Although serious muscle disorders are relatively rare, it remains crucial to understand the likelihood of these events when weighing the risks and benefits of treatment.
Dr. Ting Cai, a Research Fellow in the Nuffield Department of Primary Care Sciences at the University of Oxford and the lead author of the study, commented on the implications of the findings. He noted, "Serious muscle disorders are one of the most widely discussed concerns about statins, but our findings suggest that the risk is very low for the vast majority of people who may benefit from treatment. Understanding a person's risk can help put those concerns into perspective, support more informed treatment decisions, and provide reassurance. For the small number of people at higher risk, it gives clinicians a clearer basis for discussing monitoring, checks, or alternative treatment options."
Personalized Risk Could Improve Treatment Decisions
Professor James Sheppard, a Professor of Primary Care Research at the University of Oxford and a senior author of the study, emphasized the significance of personalized risk assessment in treatment decisions. He stated, "Treatment decisions are often based on estimates of a person's future cardiovascular risk, but much less information is available about their individual risk of adverse outcomes. This research helps address that gap by providing a way to estimate a person's risk of serious muscle disorders alongside their cardiovascular risk. Bringing those two pieces of information together could support more personalized and better-informed decisions about statin treatment."
Professor Constantinos Koshiaris, an Assistant Professor of Medical Statistics at the University of Nicosia Medical School and another senior author of the study, added, "Clinical decisions are often based on estimates of potential benefit, but understanding potential harms is equally important. This model provides a way to quantify that risk at an individual level, helping support more balanced discussions about treatment options."
By offering personalized estimates of both potential benefits and risks, the researchers hope that the calculator will empower patients and care providers to make more confident, evidence-based decisions regarding statin treatment and long-term cardiovascular disease prevention strategies. This approach aligns with a broader trend in care towards personalized medicine, which seeks to tailor medical treatment to the individual characteristics of each patient.
The online calculator, based on the model, will be available through the Oxford University Innovation software store as the STRATIFY-StatinMD Risk Calculator for academic use. This tool represents a significant advancement in the field of cardiovascular , potentially leading to improved patient outcomes and a better understanding of the risk-benefit profile of statin therapy.
The study received funding from a British Heart Foundation PhD Scholarship, with additional support for James Sheppard and Constantinos Koshiaris from the Wellcome Trust, the Royal Society, and the National Institute for and Care Research (NIHR) School for Primary Care Research. The collaborative efforts of these institutions underscore the importance of research in informing clinical practice and improving patient care in the realm of cardiovascular .
To learn more about the latest developments in Diseases & Conditions, stay updated with our exclusive reports and analyses on AILensNews.
